Clinical trials: Cancer of Brain and Nervous System
Brain and Central Nervous System Tumors
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00869401
- Testing
- dasatinib, temozolomide, radiation therapy
- Where
- 207 sites in United States
- Volunteers
- 217 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pituitary Neoplasms
Temozolomide in Aggressive Pituitary Neuroendocrine Tumors: A Latin American Multicenter Retrospective Cohort (TMZ-LATAM)
Temozolomide is the main chemotherapy drug used for aggressive pituitary tumors and pituitary carcinomas that do not respond to standard treatments like surgery or radiation.
- Trial name
- TEMPLA (NCT07695844)
- Testing
- temozolamide
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo General Hospital
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed…
- Trial name
- NCT00003464
- Testing
- temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Headache, Urinary Incontinence
Pediatric Patient Experience on a Diagnostic Path
The trial will determine the impact of an information- and education-focused interventions on the anxiety levels, and patients' experiences as well as satisfaction of patients aged 10-14 and their caregivers during the MR…
- Conditions
- Headache, Urinary Incontinence, Growth Deficiency, Visual Impairment
- Trial name
- NCT05199363
- Testing
- Information leaflet, Educational movie, Demonstration
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Children's Memorial Health Institute, Poland
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
Solid Tumors, Primary Brain Tumors
Metformin in Children With Relapsed or Refractory Solid Tumors
The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.
- Trial name
- NCT01528046
- Testing
- Vincristine, Irinotecan, Temozolomide
- Where
- 14 sites in United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Retinoblastoma, Pineoblastoma
Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging
MRI is useful for diagnosing pinealoblastoma in retinoblastoma patients
- Trial name
- NCT01884194
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Brain Tumor, Brain Pathology
Can we Use Resting-state fMRI and CSD Fiber Tractography for Presurgical Mapping?
This prospective study aims to investigate and validate the use of resting-state functional MRI (rs-fMRI) and high angular resolution diffusion imaging (HARDI), specifically constrained spherical deconvolution (CSD) tractography…
- Conditions
- Brain Tumor, Brain Pathology, Epilepsy, Vascular Malformations, Brain
- Trial name
- NCT06040580
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population.
- Trial name
- ENCEFALO (NCT06887088)
- Testing
- Encorafenib + Binimetinib, cemiplimab+fianlimab
- Where
- 18 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Brain Tumor, Glioma
The Etiology and Progression of Brain Tumors
The main goal of the study is to present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic events that represent clinically relevant new therapeutic targets and prognostic biomarkers for…
- Conditions
- Brain Tumor, Glioma, Meningioma
- Trial name
- NCT01811524
- Volunteers
- 2,000 people
- Sponsor
- Tampere University Hospital
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine…
- Trial name
- NCT07501156
- Testing
- H3K27M-EIEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Acromegaly, GEP-NET
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning…
- Trial name
- OXTEND-01 (NCT05364944)
- Testing
- Debio 4126, Sandostatin LAR, Somatuline ATG
- Where
- 14 sites in Denmark, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Debiopharm International SA
Recurrent Pituitary Adenomas
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities.
- Trial name
- TMZ-Cap (NCT03930771)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
GBM, Glioblastoma Multiforme
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific…
- Trial name
- DCVax-L EAP (NCT02146066)
- Testing
- DCVax-L
- Where
- 27 sites in United States
- Sponsor
- Northwest Biotherapeutics
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Glioblastoma Multiforme
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
- Trial name
- NCT00093964
- Testing
- Cilengitide 500 mg, Cilengitide 2000 mg
- Where
- 17 sites in United States
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Glioma
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
- Trial name
- NCT07076498
- Testing
- M032
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Brain (Nervous System) Cancers
Project MILANO: Connections Between Patients With Brain Tumors and Their Pets: an Analysis of Concerns and Needs
Context and problem In France, 61% of households own a pet, highlighting the significant role pets play in the daily lives. Patients diagnosed with brain tumors face specific challenges that may affect their ability to care their…
- Trial name
- MILANO (NCT06899516)
- Testing
- The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.